Drugs / onaBoNT-A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01050114 | Aug 2013 → Jul 2018 | overactive bladder | Christopher Patrick Smith | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04936542 | Jun 2021 → Aug 2025 | — | Ipsen | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01589263 Comparator | Jun 2012 → Sep 2019 | benign prostatic hyperplasia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT02009540 Comparator | Dec 2013 → Jan 2014 | overactive bladder | Mr HD Flood | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OnaBoNT-A | “Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).” NCT02009540 ↗ |
| Known as | onabotulinumtoxinA | “Lack of head-to-head comparative safety and efficacy data for abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) represented an important gap for informed...” PMID 42159955 ↗ May 2026 |
| Action | Inhibit | “BTX-A disrupts fusion of the acetylcholine-containing vesicle with the neuronal wall by cleaving the SNAP-25 protein in the synaptic fusion complex” PMID 18461049 ↗ May 2008 |
| Modality | Protein / enzyme biologic | “onaBoNT-A Purified Neurotoxin Complex” NCT01050114 ↗ |
| Route | Other | “200 U onaBoNT-A injected into the detrusor” NCT01050114 ↗ |